577 related articles for article (PubMed ID: 23379261)
21. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression.
Shah N; Jin K; Cruz LA; Park S; Sadik H; Cho S; Goswami CP; Nakshatri H; Gupta R; Chang HY; Zhang Z; Cimino-Mathews A; Cope L; Umbricht C; Sukumar S
Cancer Res; 2013 Sep; 73(17):5449-58. PubMed ID: 23832664
[TBL] [Abstract][Full Text] [Related]
22. [Expression of ER alpha in chemically induced MDA-MB-435 cells and its responsiveness to endocrine].
Fan J; Lu JS; Yin WJ; Lei W; Wu FY; Wu J; Hou YF; Li DQ; Di GH; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):886-9. PubMed ID: 17533736
[TBL] [Abstract][Full Text] [Related]
23. Arsenic induces functional re-expression of estrogen receptor α by demethylation of DNA in estrogen receptor-negative human breast cancer.
Du J; Zhou N; Liu H; Jiang F; Wang Y; Hu C; Qi H; Zhong C; Wang X; Li Z
PLoS One; 2012; 7(4):e35957. PubMed ID: 22558281
[TBL] [Abstract][Full Text] [Related]
24. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation.
Zhou Q; Atadja P; Davidson NE
Cancer Biol Ther; 2007 Jan; 6(1):64-9. PubMed ID: 17172825
[TBL] [Abstract][Full Text] [Related]
26. Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice.
Mai Z; Blackburn GL; Zhou JR
Carcinogenesis; 2007 Jun; 28(6):1217-23. PubMed ID: 17234721
[TBL] [Abstract][Full Text] [Related]
27. Trichostatin A and Tamoxifen inhibit breast cancer cell growth by miR-204 and ERα reducing AKT/mTOR pathway.
Liu J; Li Y
Biochem Biophys Res Commun; 2015 Nov; 467(2):242-7. PubMed ID: 26436206
[TBL] [Abstract][Full Text] [Related]
28. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
29. Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells.
Sharma D; Blum J; Yang X; Beaulieu N; Macleod AR; Davidson NE
Mol Endocrinol; 2005 Jul; 19(7):1740-51. PubMed ID: 15746193
[TBL] [Abstract][Full Text] [Related]
30. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen.
Jang ER; Lim SJ; Lee ES; Jeong G; Kim TY; Bang YJ; Lee JS
Oncogene; 2004 Mar; 23(9):1724-36. PubMed ID: 14676837
[TBL] [Abstract][Full Text] [Related]
31. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
Mai Z; Blackburn GL; Zhou JR
Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
33. GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer.
Mo Z; Liu M; Yang F; Luo H; Li Z; Tu G; Yang G
Breast Cancer Res; 2013 Nov; 15(6):R114. PubMed ID: 24289103
[TBL] [Abstract][Full Text] [Related]
34. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
35. CG0006, a novel histone deacetylase inhibitor, induces breast cancer cell death via histone-acetylation and chaperone-disrupting pathways independent of ER status.
Kim HM; Kim CS; Lee JH; Jang SJ; Hwang JJ; Ro S; Hyun YL; Choi J
Breast Cancer Res Treat; 2011 Nov; 130(2):365-75. PubMed ID: 21184271
[TBL] [Abstract][Full Text] [Related]
36. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
37. A hidden Markov model to identify combinatorial epigenetic regulation patterns for estrogen receptor α target genes.
Bonneville R; Jin VX
Bioinformatics; 2013 Jan; 29(1):22-8. PubMed ID: 23104890
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic regulation of multiple tumor-related genes leads to suppression of breast tumorigenesis by dietary genistein.
Li Y; Chen H; Hardy TM; Tollefsbol TO
PLoS One; 2013; 8(1):e54369. PubMed ID: 23342141
[TBL] [Abstract][Full Text] [Related]
39. A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cells.
Park JH; Ahn MY; Kim TH; Yoon S; Kang KW; Lee J; Moon HR; Jung JH; Chung HY; Kim HS
Invest New Drugs; 2012 Oct; 30(5):1887-98. PubMed ID: 21983700
[TBL] [Abstract][Full Text] [Related]
40. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine.
Keen JC; Yan L; Mack KM; Pettit C; Smith D; Sharma D; Davidson NE
Breast Cancer Res Treat; 2003 Oct; 81(3):177-86. PubMed ID: 14620913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
